|
ATE254136T1
(de)
*
|
1994-07-20 |
2003-11-15 |
Gen Hospital Corp |
Interaktions-fullensysteme zum nachweis von protein-interaktionen
|
|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
JPH11502717A
(ja)
|
1995-04-11 |
1999-03-09 |
ザ ジェネラル ホスピタル コーポレーション |
逆ツーハイブリッドシステム
|
|
ATE224454T1
(de)
*
|
1996-04-26 |
2002-10-15 |
Massachusetts Inst Technology |
Drei hybriden screening test
|
|
EP1241265A3
(de)
*
|
1996-04-26 |
2004-02-18 |
Massachusetts Institute Of Technology |
Screening-Verfahren für kleine Liganden
|
|
US5776689A
(en)
*
|
1996-07-19 |
1998-07-07 |
The Regents Of The University Of California |
Protein recruitment system
|
|
US5807708A
(en)
*
|
1996-07-30 |
1998-09-15 |
Millennium Pharmaceuticals, Inc. |
Conservin nucleic acid molecules and compositions
|
|
US5846722A
(en)
*
|
1996-10-16 |
1998-12-08 |
Terrapin Technologies, Inc. |
System to detect small molecule/peptide interaction
|
|
WO1998046796A1
(en)
*
|
1997-04-11 |
1998-10-22 |
The Regents Of The University Of California |
A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways
|
|
AU3587599A
(en)
*
|
1997-11-28 |
1999-06-16 |
Invitrogen Corporation |
Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
|
|
EP1035207A1
(de)
*
|
1999-03-09 |
2000-09-13 |
MultiGene Biotech GmbH |
cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
|
|
EP1792989A1
(de)
|
1999-04-12 |
2007-06-06 |
Agensys, Inc. |
13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
|
|
EP1171595A1
(de)
|
1999-04-12 |
2002-01-16 |
Agensys, Inc. |
13-transmembrane protein welches in prostatakrebs exprimiert wird
|
|
WO2001000866A1
(en)
*
|
1999-06-26 |
2001-01-04 |
Odyssey Pharmaceuticals, Inc. |
An in vivo library-versus-library selection of optimized protein-protein interactions
|
|
PT1992695E
(pt)
|
1999-08-12 |
2011-01-12 |
Agensys Inc |
Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
|
|
DE60041073D1
(de)
|
1999-10-05 |
2009-01-22 |
Agensys Inc |
G protein-gekoppelter in prostatakrebs hochexprimierter rezeptor und seine verwendungen
|
|
US6893818B1
(en)
*
|
1999-10-28 |
2005-05-17 |
Agensys, Inc. |
Gene upregulated in cancers of the prostate
|
|
US20030211495A1
(en)
*
|
2000-03-08 |
2003-11-13 |
Richard Hopkins |
Reverse n-hybrid screening method
|
|
DK1299727T3
(da)
|
2000-07-12 |
2009-06-15 |
Agensys Inc |
Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
|
|
PT1313850E
(pt)
|
2000-08-28 |
2008-11-18 |
Agensys Inc |
Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro
|
|
DE60140461D1
(de)
*
|
2000-09-11 |
2009-12-24 |
Genzyme Corp |
Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
|
|
WO2002026932A2
(en)
|
2000-09-26 |
2002-04-04 |
Duke University |
Rna aptamers and methods for identifying the same
|
|
WO2002058450A2
(en)
*
|
2000-12-22 |
2002-08-01 |
Dana-Faber Cancer Institute, Inc. |
Regulation of cell growth by muc1
|
|
AU2002231736A1
(en)
|
2000-12-22 |
2002-07-08 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Use of repulsive guidance molecule (rgm) and its modulators
|
|
US20030165873A1
(en)
|
2001-03-02 |
2003-09-04 |
Come Jon H. |
Three hybrid assay system
|
|
US6924358B2
(en)
|
2001-03-05 |
2005-08-02 |
Agensys, Inc. |
121P1F1: a tissue specific protein highly expressed in various cancers
|
|
US7271240B2
(en)
|
2001-03-14 |
2007-09-18 |
Agensys, Inc. |
125P5C8: a tissue specific protein highly expressed in various cancers
|
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
|
AU2002318112B2
(en)
|
2001-04-10 |
2007-12-06 |
Agensys, Inc. |
Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
|
|
EP1401853B1
(de)
*
|
2001-05-25 |
2010-09-22 |
Duke University |
Modulatoren pharmakologischer mittel
|
|
EP1429793B1
(de)
|
2001-09-06 |
2015-02-25 |
Agensys, Inc. |
Nucleinsäure und entsprechendes protein, steap-1, bei der behandlung und zum nachweis von krebs
|
|
US20040049024A1
(en)
*
|
2001-12-07 |
2004-03-11 |
Geoff Clark |
Compositions and methods related to the minn1 tumor suppressor gene and protein
|
|
US20040086945A1
(en)
*
|
2002-06-03 |
2004-05-06 |
The Procter & Gamble Company |
Hairless protein-interacting partner complexes and methods thereto
|
|
CA2542171C
(en)
*
|
2002-06-26 |
2015-12-15 |
Abbott Gmbh & Co. Kg |
Modulators and modulation of the interaction between rgm and neogenin
|
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
|
US20060099713A1
(en)
*
|
2002-10-01 |
2006-05-11 |
Buck Institute |
Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
|
|
CA2515699C
(en)
|
2003-02-10 |
2015-01-27 |
Aya Jakobovits |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
|
WO2004092339A2
(en)
*
|
2003-04-11 |
2004-10-28 |
Ilex Products, Inc. |
Modulation of muc1 mediated signal transduction
|
|
EP2319524B1
(de)
|
2003-05-30 |
2013-08-21 |
Agensys, Inc. |
Prostatstammzellenantigen-Varianten und Untersequenzen davon
|
|
GB0315248D0
(en)
*
|
2003-06-30 |
2003-08-06 |
Hoffmann La Roche |
HCV regulated protein expression
|
|
US8129506B2
(en)
|
2003-10-24 |
2012-03-06 |
Genzyme Corporation |
Modulation of the interaction of MUC1 with MUC1 ligands
|
|
DE602004020855D1
(de)
*
|
2003-11-20 |
2009-06-10 |
Hoffmann La Roche |
Spezifische Marker für Stoffwechselssyndrome
|
|
CA2556729A1
(en)
*
|
2004-02-23 |
2005-09-09 |
Genzyme Corporation |
Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
|
|
WO2005106042A2
(en)
|
2004-04-22 |
2005-11-10 |
Regado Biosciences, Inc. |
Improved modulators of coagulation factors
|
|
MXPA06013834A
(es)
|
2004-05-28 |
2007-03-01 |
Agensys Inc |
Anticuerpos y moleculas relacionadas que enlazan a proteinas psca.
|
|
US8034553B2
(en)
|
2004-06-24 |
2011-10-11 |
Kimberly-Clark Worldwide, Inc. |
Biomarkers for wound healing
|
|
EP3300739A3
(de)
|
2005-03-31 |
2018-07-18 |
Agensys, Inc. |
An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
|
|
CA2624562A1
(en)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
|
AU2007291448B2
(en)
|
2006-08-31 |
2014-02-20 |
Nexigen Gmbh |
Methods for detecting protein-peptide interactions
|
|
EP1927364A1
(de)
|
2006-12-01 |
2008-06-04 |
Ecole Normale Superieure De Lyon |
Polypetitde mit modulatorischer Wirkung auf Zellen
|
|
WO2008097844A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Dana -Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
|
|
WO2008097840A2
(en)
|
2007-02-02 |
2008-08-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
|
|
EP2034020A1
(de)
*
|
2007-08-30 |
2009-03-11 |
Procomcure Biotech GmbH |
Verfahren zur Herstellung eines modifizierten Peptids
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2101173A1
(de)
*
|
2008-03-14 |
2009-09-16 |
Vivalis |
In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist
|
|
WO2009138933A1
(en)
*
|
2008-05-15 |
2009-11-19 |
Koninklijke Philips Electronics N.V. |
Method and system for generating an x-ray bean
|
|
JP2013507950A
(ja)
|
2009-10-22 |
2013-03-07 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク |
グアニン交換因子インヒビター及び抗癌剤としてのその使用
|
|
CN113717286A
(zh)
|
2009-12-08 |
2021-11-30 |
Abbvie德国有限责任两合公司 |
用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
|
|
WO2011083147A1
(en)
|
2010-01-08 |
2011-07-14 |
Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh |
Wave1 inhibition in the medical intervention of inflammatory diseases and/or infections caused by a pathogen
|
|
US20130116304A1
(en)
|
2010-04-19 |
2013-05-09 |
Ernst R. Werner |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
PE20142168A1
(es)
|
2012-01-27 |
2015-01-17 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
EP3237003B1
(de)
|
2014-12-24 |
2021-08-11 |
NexImmune, Inc |
Nanopartikelzusammensetzungen und verfahren für die immuntherapie
|
|
WO2017077382A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
|
WO2017087825A1
(en)
|
2015-11-19 |
2017-05-26 |
Asclepix Therapeutics, Llc. |
Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
|
|
CN108883180B
(zh)
|
2016-02-05 |
2023-07-07 |
奥里尼斯生物科学私人有限公司 |
Clec9a结合剂及其用途
|
|
EP4276114A3
(de)
|
2016-03-07 |
2024-02-21 |
Vib Vzw |
Einzeldomänenantikörper gegen cd20
|
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
|
CA3023883A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
KR20190066040A
(ko)
|
2016-10-04 |
2019-06-12 |
아스클리픽스 테라퓨틱스, 인크. |
Tie2 신호전달을 활성화시키기 위한 화합물 및 방법
|
|
JP7204643B2
(ja)
|
2016-10-24 |
2023-01-16 |
オリオニス バイオサイエンシズ ビーブイ |
標的変異インターフェロン-ガンマおよびその使用
|
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
CA3050601A1
(en)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
|
WO2019028427A1
(en)
|
2017-08-03 |
2019-02-07 |
Asclepix Therapeutics, Llc. |
METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
|
|
WO2019075056A1
(en)
|
2017-10-10 |
2019-04-18 |
The Johns Hopkins University |
BIODEGRADABLE BIOMIMETIC PARTICLES
|
|
GB2584211B
(en)
|
2017-11-16 |
2023-05-24 |
Synthex Inc |
Selective modulation of protein-protein interactions
|
|
EP3743448A4
(de)
|
2018-01-26 |
2021-11-03 |
Orionis Biosciences, Inc. |
Xcr1-bindende wirkstoffe und verwendungen davon
|
|
AU2019215440B2
(en)
|
2018-02-05 |
2025-12-04 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
US12410225B2
(en)
|
2018-11-08 |
2025-09-09 |
Orionis Biosciences, Inc |
Modulation of dendritic cell lineages
|
|
US11254736B2
(en)
|
2019-02-15 |
2022-02-22 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
JP7570338B2
(ja)
|
2019-02-15 |
2024-10-21 |
インテグラル・モレキュラー・インコーポレイテッド |
クローディン6抗体及びその使用
|
|
CN114127298B
(zh)
|
2019-05-15 |
2025-09-02 |
辛赛克斯公司 |
蛋白质的选择性降解
|
|
JP7727628B2
(ja)
|
2019-12-03 |
2025-08-21 |
アラマー バイオサイエンシーズ, インク. |
核酸結合免疫サンドイッチアッセイ(nulisa)
|
|
GB202004514D0
(en)
|
2020-03-27 |
2020-05-13 |
Inst De Medicina Molecular Joaeo Lobo Antunes |
Treatment of Immunosuppressive Cancer
|
|
IL302068A
(en)
|
2020-10-14 |
2023-06-01 |
Viridian Therapeutics Inc |
Preparations and methods for treating eye disease of the thyroid gland
|
|
US20230084477A1
(en)
|
2021-08-10 |
2023-03-16 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2024008755A1
(en)
|
2022-07-04 |
2024-01-11 |
Vib Vzw |
Blood-cerebrospinal fluid barrier crossing antibodies
|
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
|
US12049502B2
(en)
|
2022-11-30 |
2024-07-30 |
Integral Molecular, Inc. |
Antibodies directed to claudin 6, including bispecific formats thereof
|
|
AU2024243709A1
(en)
|
2023-04-03 |
2025-11-06 |
Katholieke Universiteit Leuven |
Blood-brain barrier crossing antibodies
|
|
WO2025014774A1
(en)
|
2023-07-07 |
2025-01-16 |
Viridian Therapeutics, Inc. |
Methods of treating active and chronic thyroid eye disease
|
|
AU2024299328A1
(en)
|
2023-07-21 |
2026-01-22 |
Marrow Therapeutics, Inc. |
Hematopoietic cell targeting conjugates and related methods
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
WO2025136985A1
(en)
|
2023-12-17 |
2025-06-26 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025160334A1
(en)
|
2024-01-26 |
2025-07-31 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2026019692A2
(en)
|
2024-07-15 |
2026-01-22 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory fusion proteins and related methods
|